enVVeno Medical Reports Third Quarter 2026 Financial Results and Prepares to Treat First Patients in FDA-Approved TAVVE Pivotal Study
enVVeno Medical reported a Q3 2026 net loss of $4.4 million ($6.29 per share) and ended the quarter with $18.5 million in cash and investments, with quarterly burn of roughly $3 million. The company is on track to treat the first patients in the FDA-approved TAVVE pivotal study of its enVVe venous valve before year end, starting with a 10-patient safety stage before a 220-patient randomized stage.
Key figures
- Guidance
- Cash burn expected to rise to $4M-$5M per quarter in H1 2027 as TAVVE enrolls
- Net loss
- $4.4 million
- Cash runway
- into Q4 2027
- Operating expenses
- $4.5 million
- Quarterly cash burn
- $3 million
- Cash and investments
- $18.5 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.